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TABLE 1 Baseline Characteristics and Response to
Fibrinolytic Therapy (N ¼ 31)
Age, yrs 28  9.6
Women 16 (51.6)
Time from valve replacement to PVT, months 32 (17.75, 71.75)
Mitral PVT 21 (67.7)
NYHA functional class III/IV 20 (64.5)
Subtherapeutic INR* 20 (69)
Previous valve thrombosis 6 (19.4)
Response to ﬁbrinolytic therapy
Pre- and post-treatment mitral EDG, mm Hg 14.3, 6.2†
Pre- and post-treatment mitral MDG, mm Hg 25.5, 12‡
Pre- and post-treatment aortic PSG, mm Hg 66.5, 39.5§
Pre- and post-treatment aortic MSG, mm Hg 38.2, 22.6k
Complete failure 18 (58.1)
Partial response 13 (41.9)
Values are mean  SD, n (%), or median (IQR). *Two patients did not have baseline
INR values. †p ¼ 0.00039. ‡p ¼ 0.000066. §p ¼ 0.017. kp ¼ 0.039.
EDG ¼ end-diastolic gradient; INR ¼ international normalized ratio; MDG ¼
mean diastolic gradient; MSG ¼ mean systolic gradient; NYHA ¼ New York Heart
Association; PSG ¼ peak systolic gradient.
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1485improve by at least 1 New York Heart Association
functional class had a major complication compared
with one of 19 (5.3%) who did improve (p ¼ 0.0026).
Reduction in valve gradients with FT did not correlate
with improvement in functional class and was not
associated with the occurrence of adverse outcomes.
This is the ﬁrst report to document the occur-
rence of spontaneous valve opening after failed FT.
In a review of 243 patients in 17 retrospective
studies with failed FT, Huang et al. (3) found that
follow-up information was not available in more
than 40% of patients even for assessment of 30-day
outcomes. None of the studies followed up patients
beyond 30 days. This information is relevant for
developing countries because many patients with
residual valve dysfunction do not undergo redo
surgery.
Though spontaneous restoration of valve function
was common, the rate of major adverse events during
follow-up was high. However, these events occurred
almost exclusively in patients (6 of 7) who were in
New York Heart Association functional class III or
those who had not improved in functional class with
FT. The magnitude of reduction in transvalvular
gradients, though predictive of spontaneous valve
opening, was not associated with either improve-
ment in functional class or the occurrence of adverse
events. Transvalvular gradients are dynamic and
are inﬂuenced by many variables, including heart
rate, and may misrepresent the degree of valve
dysfunction. However, these ﬁndings are based on a
small number of patients and must be interpreted
cautiously.In conclusion, residual valve dysfunction after
FT normalizes spontaneously in nearly one-half the
patients, but the risk of major adverse events is pro-
hibitively high, particularly among patients who do
not show improvement in functional class after FT.
Thus, these patients should be triaged for early redo
surgery irrespective of the reduction in transvalvular
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Atrial Fibrillation
Ablation in Patients
With Hypertrophic
CardiomyopathyLong-Term Outcomes and Clinical PredictorsAtrial ﬁbrillation (AF) is common in patients with
hypertrophic cardiomyopathy (HCM), present in 20%
to 25% (1). Radiofrequency (RF) ablation is a safe and
effective option for selected patients with symptom-
atic AF. However, its efﬁcacy in patients with HCM
has been less studied. AF in this group may have
different mechanisms and thus, catheter ablation
may have a different effect. We compared the
FIGURE 1 Long-Term Arrhythmia Outcomes
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Kaplan-Meier survival curve showing the long-term arrhythmia-free survival off anti-
arrhythmic drugs (AADs) (A) and arrhythmia control off or on previously ineffective
AADs (B). Note the increase in efﬁcacy in both groups after repeat radiofrequency (RF)
ablation, yet the persistent lower efﬁcacy of any strategy in patients with hypertrophic
cardiomyopathy (HCM). CI ¼ conﬁdence interval.
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1486long-term clinical efﬁcacy of AF ablation between
patients with and those without HCM and aimed to
identify predictors of recurrence in patients with HCM.
We analyzed 40 patients with primary HCM (age,
54.3  7.3 years; 70% men) and symptomatic AF
(67.5% persistent) undergoing index ablation be-
tween 2006 and 2012. Their outcomes were compared
with those of 64 patients (age, 56.2  5.8 years; 70%
men) with similar AF characteristics (70.3% persis-
tent) without HCM over the same period. The diag-
nosis of HCM and classiﬁcation of AF were madeaccording to current guidelines. Patients with long-
standing persistent AF were excluded. Our standard
approach to AF ablation has been described (2). Acute
successful ablation, deﬁned as isolation of all pul-
monary veins (PVs) and ablation of sustained orga-
nized atrial tachyarrhythmias (OAT), was achieved in
all patients. Repeat procedures were performed as
clinically indicated in those with recurrence. The
median follow-up was 54 months (HCM, 22 to 67 vs.
35 to 67 comparison; p ¼ 0.66). The HCM group
had a mean left ventricular (LV) wall thickness
of 17.5  2.8 mm. LV outﬂow obstruction at rest
was present in 37.5% of patients with HCM (mean
gradient, 37  12.5 mm Hg).
The 1-year arrhythmia-free survival off anti-
arrhythmic drugs (AADs) was lower in the HCM
group (42.5% vs. 70.3%; p ¼ 0.005), and the ablation
efﬁcacy declined until the end of follow-up (35% vs.
67.2%; p ¼ 0.001). The recurrent arrhythmia was
AF in all (n ¼ 26) with HCM (vs. 95% [n ¼ 20] in non-
affected), along with coexisting OAT in 34.5% (n ¼ 9)
(vs. 14.5% [n ¼ 3] in non-affected). Twelve patients
in the HCM group (30%) underwent a single repeat
ablation and 1 patient underwent 2 repeat ablations
(mean 1.32  0.5). In the non-affected group, 12 pa-
tients (18.8%) underwent a single redo; none had a
third procedure (mean, 1.18  0.4; p ¼ 0.7). Most pa-
tients had chronic PV reconnection (HCM, 61.5% vs.
91.6% in non-affected cohort; p ¼ 0.0004), whereas
the remaining patients had OATs that were mapped
and ablated. Repeat procedures resulted in improved
arrhythmia freedom; however, the effect on patients
with HCM was lower (1 year: 45% vs. 75%; p ¼ 0.001;
end of follow-up: 47.5% vs. 73.4%; p ¼ 0.005)
(Figure 1A). Similarly, arrhythmia control, deﬁned as
maintenance of sinus rhythm with or without AADs,
was also lower (60% vs. 82.8%; p ¼ 0.01) (Figure 1B).
Patients with HCM were more likely to require
chronic AADs (45% vs. 18.8%; p ¼ 0.007), predomi-
nantly amiodarone (77.8% vs. 16.6%; p ¼ 0.005).
Patients with HCM who had arrhythmia recurrence
were more likely to have LV outﬂow obstruction
(57.7% vs. 0%; p < 0.0001), with only 20.8% main-
taining sinus rhythm at the end of follow-up. LV
outﬂow obstruction was an independent predictor of
arrhythmia recurrence (hazard ratio: 4.3; 1.6 to 11.4;
p ¼ 0.0007). Baseline left atrial pressure $12 mm Hg
(hazard ratio: 3.1; 1.4 to 7.1; p ¼ 0.005) and dilated left
atrium (1.06; 1.003 to 1.11 per mm; p ¼ 0.04) were
associated with recurrence only in univariate anal-
ysis. Procedure-related complications were rare.
However, median hospitalization was longer in the
HCM group (2 [1 to 6] vs. 1 [1 to 3] days; p < 0.0001),
with a higher readmission rate at 30 days (25% vs.
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congestive symptoms.
Our study is the ﬁrst comparing long-term
arrhythmia control among patients with HCM and a
non-affected cohort. We found that the efﬁcacy of AF
ablation is signiﬁcantly lower compared with non-
affected patients, irrespective of the number of pro-
cedures or use of AADs (3). In fact, these are
frequently required. Potential explanations include
anatomic variations in atrial thickness in patients
with HCM as well as different AF substrate and non-
PV triggers. In this study, re-isolation of all chroni-
cally reconnected PVs did not improve arrhythmia
control in patients with HCM to the same extent as
that in non-affected subjects. Our results indicate
that AF ablation is safe in the HCM population,
although it can be associated with signiﬁcant post-
procedural volume retention and pulmonary edema
requiring treatment. When present, LV outﬂow
obstruction is a strong predictor of recurrence.Fernando M. Contreras-Valdes, MD
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Platelets Interplay
Between Pneumonia and
Cardiovascular EventsEstablishing a Link?We read with interest the study by Cangemi et al. (1)
entitled “Platelet Activation Is Associated WithMyocardial Infarction in Patients With Pneumonia.”
The authors aimed to shed light on the role of platelet
activation in hospitalized patients with community-
acquired pneumonia (CAP) and myocardial infarc-
tion (MI). Although the ﬁndings of the present study
were also discussed in a well-written editorial by
Santos-Gallego and Badimon (2), we believe that
several issues need to be highlighted and further
clariﬁed in this ﬁeld.
First, both Cangemi et al. (1) and Santos-Gallego
and Badimon (2) support the pathophysiological
link between pneumonia and acute cardiovascular
events with data from the long-lasting infection
hypothesis that implicated microorganisms in
atherosclerosis. It should be noted, however, that no
clear proof of this hypothesis exists, especially after
the failure of antibiotic trials (3). Of note, inﬂuenza
viruses that are mentioned as an example of this
link in both papers account for only 11% of CAP in
hospitalized patients (4).
Furthermore, hospitalized patients with CAP are
characterized by an increased rate of comorbidities
compared with patients not requiring hospitalization.
Comorbidities, such as cardiovascular and cerebro-
vascular disease, diabetes, hypertension, renal fail-
ure, chronic obstructive pulmonary disease, and
peripheral arterial disease, that were present in the
study’s population are well-known entities with
increased platelet reactivity and already established
atherosclerotic alterations (5). Therefore, enhanced
platelet reactivity was probably evident before the
CAP diagnosis in these patients. This hypothesis is
supported by the ﬁnding that higher soluble P-selec-
tin levels were also detected in patients with isolated
increased troponin, but without MI, that were char-
acterized by a higher prevalence of comorbidities.
This result could be explained by the fact that
P-selectin, apart from being a marker of increased
platelet activation through platelet adhesion to
monocytes, also initiates a series of functional re-
sponses implicated in the pathogenesis of athero-
sclerosis, such as transfer of tissue factor to
monocytes, ﬁbrin deposition to growing thrombus,
and superoxide anion and cytokines production by
leukocyte. In that way, P-selectin mediates impor-
tantly the inﬂammatory process of atherosclerosis
and high serum levels of this molecule indicate also
an enhanced atherosclerotic burden that these pa-
tients most likely exhibit as a result of their comor-
bidities. The same applies for CD40L, which induces
the production of chemokines and expression of
adhesion molecules by endothelial cells, thereby
initiating an inﬂammatory response at sites of
vascular injury. Thus, the lack of data on platelet
